Successful treatment of atopic dermatitis with house dust mite sublingual immunotherapy tablets.

IF 2.3 4区医学 Q3 ALLERGY

Asian Pacific journal of allergy and immunology Pub Date : 2024-09-01 DOI:10.12932/AP-231120-1004

Ploykarn Kiatiwat, Wat Mitthamsiri, Tadech Boonpiyathad, Panitan Pradubpongsa, Atik Sangasapaviliya

{"title":"Successful treatment of atopic dermatitis with house dust mite sublingual immunotherapy tablets.","authors":"Ploykarn Kiatiwat, Wat Mitthamsiri, Tadech Boonpiyathad, Panitan Pradubpongsa, Atik Sangasapaviliya","doi":"10.12932/AP-231120-1004","DOIUrl":null,"url":null,"abstract":"Background: Atopic dermatitis (AD) is the most common chronic inflammatory skin disease. Allergen-specific immunotherapy is a treatment option for selected patients with severe AD sensitization to house dust mites (HDM).Objective: To report the first case of successful treatment with HDM sublingual immunotherapy (SLIT) tablets in patients with severe AD.Methods: A Thai male patient with HDM sensitization and severe AD who had not responded to topical corticosteroids and calcineurin inhibitors underwent 1 month of HDM subcutaneous immunotherapy (SCIT), after which his skin symptoms were minimally improved. He lost follow-up SCIT and the symptoms worsened, with large wheal lesions appearing at the SCIT injection site, so we decided to switch from SCIT to HDM SLIT tablets.Results: After the SLIT treatment, the AD and skin lesions improved and the medication could be stopped.Conclusions: HDM SLIT might be an alternative treatment in patients with HDM sensitization and severe AD who are refractory to conventional treatment.","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":"253-257"},"PeriodicalIF":2.3000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Pacific journal of allergy and immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.12932/AP-231120-1004","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Atopic dermatitis (AD) is the most common chronic inflammatory skin disease. Allergen-specific immunotherapy is a treatment option for selected patients with severe AD sensitization to house dust mites (HDM).

Objective: To report the first case of successful treatment with HDM sublingual immunotherapy (SLIT) tablets in patients with severe AD.

Methods: A Thai male patient with HDM sensitization and severe AD who had not responded to topical corticosteroids and calcineurin inhibitors underwent 1 month of HDM subcutaneous immunotherapy (SCIT), after which his skin symptoms were minimally improved. He lost follow-up SCIT and the symptoms worsened, with large wheal lesions appearing at the SCIT injection site, so we decided to switch from SCIT to HDM SLIT tablets.

Results: After the SLIT treatment, the AD and skin lesions improved and the medication could be stopped.

Conclusions: HDM SLIT might be an alternative treatment in patients with HDM sensitization and severe AD who are refractory to conventional treatment.

查看原文本刊更多论文

使用屋尘螨舌下免疫疗法片剂成功治疗特应性皮炎。

背景：特应性皮炎（AD）是最常见的慢性炎症性皮肤病：特应性皮炎（AD）是最常见的慢性炎症性皮肤病。过敏原特异性免疫疗法是治疗某些对屋尘螨（HDM）过敏的重症特应性皮炎患者的一种选择：报告首例使用 HDM 舌下免疫疗法（SLIT）片剂成功治疗严重 AD 患者的病例：一名泰国男性患者因HDM致敏而患有严重的AD，对外用皮质类固醇激素和钙神经蛋白抑制剂无效，接受了为期1个月的HDM皮下免疫疗法（SCIT），之后他的皮肤症状略有改善。他失去了后续的 SCIT 治疗，而且症状恶化，SCIT 注射部位出现了大面积的荨麻疹皮损，因此我们决定将 SCIT 改为 HDM SLIT 片剂：结果：SLIT 治疗后，AD 和皮损有所改善，可以停药：结论：对于常规治疗无效的 HDM 致敏和严重 AD 患者，HDM SLIT 可能是一种替代治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Asian Pacific journal of allergy and immunology 医学-过敏

CiteScore

12.80

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： The Asian Pacific Journal of Allergy and Immunology (APJAI) is an online open access journal with the recent impact factor (2018) 1.747 APJAI published 4 times per annum (March, June, September, December). Four issues constitute one volume. APJAI publishes original research articles of basic science, clinical science and reviews on various aspects of allergy and immunology. This journal is an official journal of and published by the Allergy, Asthma and Immunology Association, Thailand. The scopes include mechanism, pathogenesis, host-pathogen interaction, host-environment interaction, allergic diseases, immune-mediated diseases, epidemiology, diagnosis, treatment and prevention, immunotherapy, and vaccine. All papers are published in English and are refereed to international standards.